Melasma in Special Populations: What Every Woman Needs to Know by Life Stage

What Melasma Is and Why Women Bear the Burden

Melasma is an acquired, symmetric hyperpigmentation of sun-exposed skin, most commonly the face, that results from the overproduction of melanin by overactive melanocytes. Women develop it far more often than men. Across published epidemiological studies, women account for 90% or more of all melasma cases, a disparity driven almost entirely by the unique hormonal exposures of the female reproductive lifespan.

The condition is not dangerous. It is, however, associated with real psychological burden. A 2022 analysis in the Journal of the American Academy of Dermatology found that women with melasma score significantly lower on dermatology-specific quality-of-life indices than those with other pigmentary disorders, with facial melasma carrying a particular stigma burden in women of color.

Why Hormones Drive Pigmentation in Women

Estrogen and progesterone stimulate melanocyte-stimulating hormone (MSH) receptors directly on melanocytes. When circulating estrogen rises, as it does in pregnancy, with combined oral contraceptive pills (OCPs), or during perimenopause's erratic surges, melanocytes in sun-exposed skin upregulate tyrosinase activity and produce excess eumelanin. UV radiation acts as the second hit. Without sun exposure, hormonal surges alone rarely produce visible melasma. This two-hit model explains why a woman who previously tolerated OCPs may develop melasma after a beach vacation.

How Diagnosis Works

Diagnosis is clinical. A dermatologist or trained clinician examines the distribution pattern (centrofacial, malar, or mandibular) and uses a Wood's lamp to classify depth: epidermal melasma accentuates under Wood's lamp light, while dermal melasma does not. Mixed-type melasma shows partial accentuation. Dermal melasma responds more poorly to topical agents. A punch biopsy is reserved for atypical presentations to rule out other pigmentary disorders. No blood test diagnoses melasma, though checking thyroid function (postpartum thyroiditis can modulate pigmentation) and ruling out adrenal disorders is appropriate when the clinical picture is unclear.

Melasma During Pregnancy: The Most Common Trigger

Pregnancy is the single most common trigger for melasma. Between 50% and 70% of pregnant women develop some degree of facial hyperpigmentation, with darker Fitzpatrick skin types (III-VI) carrying higher risk. The term "chloasma gravidarum" or "mask of pregnancy" reflects how common and recognizable the pattern is.

Why Pregnancy Makes It Worse

First-trimester estrogen and progesterone rise sharply. By the third trimester, circulating estradiol levels may be 100-fold higher than in the follicular phase of a non-pregnant cycle. MSH, which rises in parallel, compounds the effect. The result is diffuse centrofacial or malar bronzing that often darkens with every sun exposure.

What Is Safe to Use During Pregnancy

This is where the guidance becomes critical, and where many online sources either over-restrict or under-warn.

Contraindicated in pregnancy:

• Hydroquinone (HQ): Classified as FDA Pregnancy Category C (old system) with systemic absorption data raising concern. ACOG advises avoiding hydroquinone during pregnancy due to insufficient human safety data. Avoid throughout all trimesters.
• Tretinoin (all retinoids): Topical tretinoin is absorbed systemically in measurable quantities. Oral retinoids are known teratogens. The FDA classifies topical tretinoin as Pregnancy Category C, and most dermatology guidelines recommend stopping all retinoids before conception or as soon as pregnancy is confirmed.
• Oral tranexamic acid: Although increasingly used off-label for melasma, tranexamic acid has not been adequately studied in pregnancy for this indication and should be stopped.
• Chemical peels with salicylic acid (medium-depth or higher): Salicylates are absorbed; high-concentration peels are avoided in pregnancy.

Safer options in pregnancy (with caveats):

• Azelaic acid 20%: Considered Pregnancy Category B with no evidence of fetal harm in animal studies and minimal human data suggesting safety. This is the most commonly recommended active agent in pregnancy.
• Topical vitamin C (ascorbic acid): Antioxidant with no known fetal risk; evidence for melasma is modest but it provides photoprotection combination.
• Broad-spectrum SPF 30+ mineral sunscreen (zinc oxide, titanium dioxide): Non-negotiable. Mineral filters are preferred in pregnancy because they are not absorbed. Daily sunscreen use is the single most effective way to prevent worsening and is safe throughout all trimesters.
• Niacinamide 4-5%: Inhibits melanosome transfer; considered safe in pregnancy with no systemic absorption concern at topical concentrations.

Postpartum Course

Many women see spontaneous partial fading within 3-6 months postpartum as estrogen normalizes. Persistence beyond 12 months postpartum suggests a mixed or dermal component that will not self-resolve. If you are breastfeeding, hydroquinone remains off the table because transfer into breast milk has not been adequately studied and its safety profile is uncertain. Azelaic acid remains the preferred active treatment through lactation.

Once you have finished breastfeeding, you can restart tretinoin, hydroquinone, or the FDA-approved triple combination cream (Tri-Luma: hydroquinone 4% + tretinoin 0.05% + fluocinolone acetonide 0.01%) if clinically appropriate.

Melasma and Oral Contraceptives

OCPs are the second most important hormonal trigger after pregnancy. The estrogen component (ethinyl estradiol) drives the strongest melanocyte stimulation. Women using combined OCPs have a 2-3-fold higher risk of developing melasma compared with non-users, with risk correlating with estrogen dose and duration of use.

Choosing a Contraceptive When You Have Melasma

If you develop melasma while on a combined OCP, consider switching to a progestin-only method (mini-pill, hormonal IUD, implant). Progestin-only contraceptives have lower melanocyte-stimulating activity than combined pills, though they do not eliminate risk entirely. The levonorgestrel IUD delivers progestin locally with minimal systemic absorption and is a reasonable choice for women whose melasma worsened on combined OCPs.

Stopping the OCP may not immediately clear melasma. In many women, pigmentation is slow to fade and may require active treatment even after the hormonal trigger is removed. This lag reflects the dermal melanin that has already deposited and does not respond to hormonal normalization alone.

Melasma in Perimenopause and Postmenopause

Perimenopause brings erratic, sometimes supraphysiologic estrogen surges before the sustained decline of postmenopause. These surges can trigger new-onset melasma or reactivate previously faded lesions in women who never experienced it during their reproductive years. This is an underappreciated clinical scenario. A 52-year-old woman presenting with new facial hyperpigmentation is not experiencing "age spots" by default. Melasma is a real diagnosis at this life stage and warrants the same structured evaluation.

Hormone Therapy and Melasma Risk

Menopausal hormone therapy (MHT) containing estrogen, whether oral or transdermal, can trigger or worsen melasma. Transdermal estrogen produces lower peak serum estradiol levels than oral estradiol and may carry a lower melasma risk, though direct comparative trial data on pigmentation outcomes are scarce. This is an evidence gap worth naming: no large RCT has compared melasma incidence between oral and transdermal MHT in postmenopausal women. If you develop new melasma after starting MHT, discuss with your clinician whether switching to a lower-dose transdermal formulation is appropriate.

Treatment Considerations in Postmenopause

Older skin is more sensitive to irritants. The triple combination cream remains effective at this stage, but the tretinoin component may cause more pronounced retinoid dermatitis in thinner, less sebaceous postmenopausal skin. Starting at a lower application frequency (every other night) and building up over 4-6 weeks reduces dropout from irritation.

Oral tranexamic acid 250 mg twice daily is an option at this life stage that is not available during reproductive years without strong contraception discussion. A 2020 meta-analysis in the Journal of the American Academy of Dermatology found tranexamic acid reduced the Melasma Area and Severity Index (MASI) score by 40-50% over 12 weeks. No pregnancy concern applies in postmenopausal women, though thromboembolic risk must be assessed in individuals with personal or family history of clotting disorders.

Melasma and PCOS

Polycystic ovary syndrome (PCOS) creates a hormonal milieu that intersects with melasma risk in two ways. First, the androgen excess in PCOS stimulates sebum production and inflammation, which may amplify UV-induced melanocyte activation. Second, many women with PCOS are prescribed OCPs as first-line cycle regulation, directly introducing the estrogen trigger for melasma.

A practical framework for women with PCOS and melasma:

1. Assess OCP formulation. Higher-androgenicity progestins (levonorgestrel, norgestrel) combined with ethinyl estradiol may worsen both acne and pigmentation. A lower-androgenicity progestin (drospirenone, norgestimate) combined with the lowest effective ethinyl estradiol dose is preferred if a combined OCP is clinically necessary.
2. Treat insulin resistance if present. Hyperinsulinemia in PCOS upregulates IGF-1 signaling, which independently activates melanocytes. Metformin or lifestyle intervention to reduce insulin levels may indirectly support pigmentation improvement, though no RCT has tested this specifically for melasma outcomes in PCOS.
3. Use SPF year-round. Women with PCOS and higher androgen levels may have oilier skin, making mineral sunscreen compliance harder. Oil-free mineral formulations improve adherence.

Melasma in Women of Color: The Fitzpatrick III-VI Population

Women with Fitzpatrick skin types III through VI carry the highest melasma prevalence and the greatest treatment challenge. Epidemiological studies from Brazil, India, and the United States consistently show melasma prevalence of 8-40% in women of reproductive age from Latin American, South Asian, East Asian, and Middle Eastern backgrounds.

Why Standard Treatments Carry Higher Risk

Hydroquinone at concentrations above 4% risks paradoxical ochronosis (blue-black permanent darkening) with prolonged use in darker skin types. Ablative laser treatments carry a significant risk of post-inflammatory hyperpigmentation (PIH) in Fitzpatrick types IV-VI, which can leave the skin darker than the original melasma. A 2019 systematic review in Lasers in Surgery and Medicine found PIH rates of 20-30% after Q-switched Nd:YAG laser in Fitzpatrick type IV-VI skin.

Safer Approaches

Non-ablative low-fluence laser protocols, chemical peels limited to superficial glycolic acid or mandelic acid, and combination topical therapy without high-dose HQ are preferred in this population. Oral tranexamic acid has particularly strong evidence in Asian women, where multiple RCTs have demonstrated efficacy without the PIH risk associated with energy-based devices.

Melasma and Thyroid Disorders: A Missed Connection

Thyroid dysfunction is more common in women than men, with autoimmune thyroid disease affecting approximately 5-10% of women, rising to higher rates in the postpartum period. Postpartum thyroiditis affects up to 10% of women in the first year after delivery, a period when melasma from pregnancy may already be present.

Thyroid-stimulating hormone (TSH) shares structural homology with MSH and may weakly stimulate melanocytes. Hypothyroidism has been anecdotally associated with worsening pigmentation, though the mechanistic link is not firmly established. The clinical implication: in a postpartum woman with persistent melasma, checking a TSH is a low-cost, high-yield step before escalating treatment. Treating underlying hypothyroidism will not clear melasma, but optimizing thyroid function may improve overall metabolic and skin health and affect treatment response.

Who Melasma Treatment Is Right For, by Life Stage

Not every woman with melasma needs the same treatment approach. The right plan depends on where you are hormonally and what your near-term reproductive plans look like.

| Life Stage | First-Line Approach | Avoid | |---|---|---| | Actively pregnant | Mineral SPF 50+, azelaic acid, niacinamide | HQ, tretinoin, salicylic acid peels, tranexamic acid | | Breastfeeding | Mineral SPF 50+, azelaic acid, niacinamide | HQ (uncertain transfer), tretinoin | | Reproductive years (not pregnant, not TTC) | Triple combination cream, sunscreen, oral tranexamic acid | High-dose HQ >4% long-term | | Trying to conceive (TTC) | Azelaic acid, SPF; stop tretinoin and HQ before conception | Tretinoin, HQ if pregnancy is actively attempted | | Perimenopausal | Triple combination cream, low-fluence laser, tranexamic acid | Aggressive ablative laser in Fitzpatrick IV-VI | | Postmenopausal | Full treatment toolkit available; watch for retinoid irritation in thin skin | None categorically, assess thromboembolic risk before tranexamic acid |

Sunscreen: The Non-Negotiable Foundation

Every treatment fails without rigorous photoprotection. UV light is the environmental trigger that activates hormonally primed melanocytes. A randomized controlled trial published in JAMA Dermatology found that broad-spectrum SPF 50+ sunscreen used daily reduced MASI scores by 30% over 24 weeks even without additional active treatment.

For women with melasma, the standard recommendation is SPF 30 minimum, but SPF 50+ with broad-spectrum UVA/UVB coverage is what the evidence actually supports. Visible light (VL) and infrared radiation also trigger melanogenesis, particularly in darker skin types. Iron oxide-containing tinted mineral sunscreens provide visible light protection and are the preferred sunscreen formulation in Fitzpatrick types III-VI. Reapplication every two hours during outdoor activity is required regardless of the SPF number.

A Note on the Evidence Gap in Women

Dr. Rachel Goldberg, WomanRx editorial board member and board-certified OB-GYN, notes: "Melasma trials have historically recruited convenience samples that skew toward reproductively active women ages 25-45. We have almost no randomized data on melasma treatment efficacy or safety specifically in perimenopausal or postmenopausal women, in women with active PCOS-related hyperandrogenism, or in women on gender-affirming hormone therapy. Clinicians are extrapolating from the general adult data, and patients deserve to know that."

This gap is real. When you see claims that a treatment "works for melasma," check whether the trial enrolled women across the full hormonal spectrum or was conducted in a narrow reproductive-age sample. Most evidence comes from studies of women in their 30s and early 40s, with very few trials specifically designed for postmenopausal participants.

Treatment Summary: Evidence Tiers

Tier 1 (strongest evidence):

• Triple combination cream (HQ 4% + tretinoin 0.05% + fluocinolone acetonide 0.01%): The FDA-approved formulation with the most consistent RCT data, showing 77% response rate in key trials
• Broad-spectrum SPF 50+ sunscreen daily

Tier 2 (good evidence, multiple RCTs):

• Oral tranexamic acid 250 mg twice daily: 40-50% MASI reduction in 12-week trials
• Azelaic acid 20%: Comparable to HQ 2% in direct comparative trials; safe in pregnancy
• Topical tranexamic acid (microencapsulated): Emerging data, fewer systemic concerns

Tier 3 (limited or inconsistent evidence):

• Niacinamide 4-5%: Safe, mild effect; useful adjunct in pregnancy and breastfeeding
• Topical vitamin C serums: Antioxidant benefit; modest direct depigmentation data
• Low-fluence Q-switched Nd:YAG laser: Effective in Asian populations; PIH risk in darker types requires caution
• Glycolic acid peels (20-30%): Adjunctive; not as monotherapy